LEPROTL1

Summary

LEPROTL1 (leptin receptor overlapping transcript like 1, HGNC:6555) is a protein-coding gene on chromosome 8p12, encoding Leptin receptor overlapping transcript-like 1 (O95214). Negatively regulates growth hormone (GH) receptor cell surface expression in liver.

Enables identical protein binding activity. Predicted to be involved in late endosome to vacuole transport via multivesicular body sorting pathway and negative regulation of growth hormone receptor signaling pathway. Predicted to be located in membrane. Predicted to be active in endosome.

Source: NCBI Gene 23484 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_015344

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6555
Approved symbol	LEPROTL1
Name	leptin receptor overlapping transcript like 1
Location	8p12
Locus type	gene with protein product
Status	Approved
Aliases	my047, Vps55
Ensembl gene	ENSG00000104660
Ensembl biotype	protein_coding
OMIM	607338
Entrez	23484

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 nonsense_mediated_decay

ENST00000321250, ENST00000442880, ENST00000518001, ENST00000518192, ENST00000519466, ENST00000520682, ENST00000520739, ENST00000523116, ENST00000650149

RefSeq mRNA: 2 — MANE Select: NM_015344 NM_001128208, NM_015344

CCDS: CCDS47834, CCDS6075

Canonical transcript exons

ENST00000321250 — 4 exons

Exon	Start	End
ENSE00001281725	30101898	30101973
ENSE00001778818	30105746	30108524
ENSE00002094601	30095408	30095528
ENSE00003583981	30104300	30104486

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 96.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.8660 / max 1209.3982, expressed in 1826 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88279	59.1813	1826
88278	0.2451	52
88280	0.2187	46
88277	0.1341	38
88281	0.0634	28
88282	0.0233	6

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	96.60	gold quality
cortical plate	UBERON:0005343	95.12	gold quality
adrenal tissue	UBERON:0018303	94.96	gold quality
blood	UBERON:0000178	94.83	gold quality
ganglionic eminence	UBERON:0004023	94.64	gold quality
endothelial cell	CL:0000115	94.58	gold quality
ventricular zone	UBERON:0003053	94.10	gold quality
embryo	UBERON:0000922	93.79	gold quality
left adrenal gland	UBERON:0001234	93.73	gold quality
stromal cell of endometrium	CL:0002255	93.55	gold quality
right adrenal gland	UBERON:0001233	93.51	gold quality
left adrenal gland cortex	UBERON:0035825	93.37	gold quality
islet of Langerhans	UBERON:0000006	93.31	gold quality
right adrenal gland cortex	UBERON:0035827	93.30	gold quality
adrenal gland	UBERON:0002369	93.17	gold quality
leukocyte	CL:0000738	93.05	gold quality
oocyte	CL:0000023	92.78	gold quality
mononuclear cell	CL:0000842	92.77	gold quality
monocyte	CL:0000576	92.76	gold quality
granulocyte	CL:0000094	92.71	gold quality
secondary oocyte	CL:0000655	92.71	gold quality
adrenal cortex	UBERON:0001235	92.61	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.25	gold quality
vermiform appendix	UBERON:0001154	92.06	gold quality
placenta	UBERON:0001987	92.00	gold quality
myocardium	UBERON:0002349	92.00	gold quality
lymph node	UBERON:0000029	91.94	gold quality
bone marrow	UBERON:0002371	91.72	gold quality
sperm	CL:0000019	91.58	gold quality
testis	UBERON:0000473	91.57	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-GEOD-149689	yes	754.93
E-MTAB-9221	yes	662.16
E-HCAD-4	yes	607.96
E-MTAB-8142	yes	91.37
E-CURD-122	yes	77.29
E-MTAB-9467	yes	75.96
E-CURD-46	yes	52.44
E-HCAD-8	yes	49.11
E-CURD-88	yes	45.68
E-GEOD-135922	yes	28.20
E-HCAD-10	yes	20.54
E-ANND-3	yes	15.61
E-CURD-112	yes	10.37
E-MTAB-6379	no	2088.87
E-CURD-97	no	1785.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting LEPROTL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-106A-3P	99.53	67.58	995
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-8070	99.07	69.30	1303
HSA-MIR-8066	99.05	68.66	1532
HSA-MIR-758-3P	98.42	68.60	1122
HSA-MIR-6890-3P	97.50	65.71	997
HSA-MIR-6760-3P	96.35	68.31	1001
HSA-MIR-4423-5P	95.24	64.42	454
HSA-MIR-1247-3P	83.69	63.18	99

Literature-anchored findings (GeneRIF, showing 3)

• Transgenic mice expressing either human LEPROT or human LEPROTL1 displayed growth retardation, reduced plasma IGF1 levels, and impaired hepatic sensitivity to GH, as measured by STAT5 phosphorylation and Socs2 mRNA expression. (PMID:19907080)
• these results identify endospanin-2 as a potentially novel player in skeletal muscle metabolism, plasticity, and function. (PMID:29720572)
• Promoter Mutation Analysis of LEPROTL1 Gene in Acute Leukemias and Solid Tumors. (PMID:30943467)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000104871
mus_musculus	Leprotl1	ENSMUSG00000031513
rattus_norvegicus	Leprotl1	ENSRNOG00000012601
drosophila_melanogaster	CG30423	FBGN0050423
caenorhabditis_elegans		WBGENE00016244

Paralogs (1): LEPROT (ENSG00000213625)

Protein

Protein identifiers

Leptin receptor overlapping transcript-like 1 — O95214 (reviewed: O95214)

Alternative names: Endospanin-2

All UniProt accessions (9): A0A3B3IS19, C9JVM4, E5RHU8, E5RIL0, E5RIQ0, E5RJS9, O95214, H0YBC1, Q6FHL7

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates growth hormone (GH) receptor cell surface expression in liver. May play a role in liver resistance to GH during periods of reduced nutrient availability.

Subunit / interactions. Interacts with RAB13.

Subcellular location. Membrane.

Tissue specificity. Widely expressed, with highest expression in heart, testis, adrenal gland, thymus, and spleen, and lowest expression in lung and skeletal muscle.

Similarity. Belongs to the OB-RGRP/VPS55 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O95214-1	1	yes
O95214-2	2

RefSeq proteins (2): NP_001121680, NP_056159* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007262	Vps55/LEPROT	Family

Pfam: PF04133

UniProt features (7 total): transmembrane region 4, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95214-F1	81.85	0.40

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 302 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, HORIUCHI_WTAP_TARGETS_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, MORF_MSH3, MODULE_255, ATACCTC_MIR202, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_BRCA1, MORF_ATRX, MODULE_317, GOBP_VACUOLAR_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (2): late endosome to vacuole transport via multivesicular body sorting pathway (GO:0032511), negative regulation of growth hormone receptor signaling pathway (GO:0060400)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (2): endosome (GO:0005768), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endosome transport via multivesicular body sorting pathway	1
late endosome to vacuole transport	1
negative regulation of signal transduction	1
growth hormone receptor signaling pathway	1
regulation of growth hormone receptor signaling pathway	1
protein binding	1
binding	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

578 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LEPROTL1	LEPR	P48357	736
LEPROTL1	TBC1D12	O60347	615
LEPROTL1	PLEKHS1	Q5SXH7	540
LEPROTL1	WDR74	Q6RFH5	504
LEPROTL1	LEP	P41159	483
LEPROTL1	TM4SF19	Q96DZ7	468
LEPROTL1	ZC3H8	Q8N5P1	466
LEPROTL1	RSPRY1	Q96DX4	456
LEPROTL1	GHR	P10912	452
LEPROTL1	MNMIP1	A4FU49	451
LEPROTL1	NAA30	Q147X3	450
LEPROTL1	SHISA4	Q96DD7	447
LEPROTL1	LRRC40	Q9H9A6	446
LEPROTL1	MOCS1	Q9NZB8	437
LEPROTL1	INS	P01308	433

IntAct

241 interactions, top by confidence:

A	B	Type	Score
LEPROTL1	EDA	psi-mi:“MI:0915”(physical association)	0.670
LEPROTL1	MSR1	psi-mi:“MI:0915”(physical association)	0.670
NDUFA3	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
TMEM60	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
ORMDL1	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
C2CD2L	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
NRM	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
TSPAN2	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	SLC7A1	psi-mi:“MI:0915”(physical association)	0.560
YIPF2	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	GJA8	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	CISD2	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	MFSD14B	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	FFAR2	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	SLC35C2	psi-mi:“MI:0915”(physical association)	0.560
PEX16	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	KCNJ6	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	SCN3B	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	TMX2	psi-mi:“MI:0915”(physical association)	0.560
TMEM19	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (80): LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Affinity Capture-RNA), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid), LEPROTL1 (Two-hybrid)

ESM2 similar proteins: A1CKG4, A1D708, A2XSY1, A4R2N5, A6QRX6, A6RRF7, A7EMV1, B0XXU1, B2AR67, O46521, O95214, O95807, P13498, P52650, Q0CNZ5, Q0JDK9, Q0V0G4, Q17QF8, Q1E1E0, Q28F21, Q2GSS4, Q32PD8, Q39080, Q3ZBX1, Q4WXT2, Q566G2, Q5PQQ4, Q5R5Z8, Q5RDE9, Q61462, Q62737, Q6CC06, Q6GM42, Q6GPA8, Q6P0C7, Q6PDU4, Q7S693, Q8K3C0, Q8TAC9, Q92535

Diamond homologs: B3Y064, B9TRX0, O15243, O89013, O95214, P47111, Q18319, Q32PD8, Q3SYT0, Q561T9, Q5PSV5, Q5RDE9, Q5ZJD9, Q6PDU4, Q9CQ74, Q9JLS8, Q54VP1, Q9AST6, Q9UUH1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1341 predictions. Top by Δscore:

Variant	Effect	Δscore
8:30095528:GGTG:G	donor_loss	1.0000
8:30095529:G:C	donor_loss	1.0000
8:30101894:GCAGC:G	acceptor_loss	1.0000
8:30101895:CAG:C	acceptor_loss	1.0000
8:30101896:A:AG	acceptor_gain	1.0000
8:30101896:A:AT	acceptor_loss	1.0000
8:30101897:G:GG	acceptor_gain	1.0000
8:30101897:GCTTT:G	acceptor_gain	1.0000
8:30101970:ACAAG:A	donor_loss	1.0000
8:30101971:CAAGT:C	donor_loss	1.0000
8:30101973:AG:A	donor_loss	1.0000
8:30101974:G:GG	donor_gain	1.0000
8:30101974:G:T	donor_loss	1.0000
8:30104335:T:G	acceptor_gain	1.0000
8:30104484:CTGGT:C	donor_loss	1.0000
8:30104485:TGGTA:T	donor_loss	1.0000
8:30104487:G:GA	donor_loss	1.0000
8:30104487:G:GG	donor_gain	1.0000
8:30104488:TAAG:T	donor_loss	1.0000
8:30138605:T:C	donor_gain	1.0000
8:30156403:AGAGG:A	donor_loss	1.0000
8:30156404:GAG:G	donor_gain	1.0000
8:30156404:GAGG:G	donor_loss	1.0000
8:30156407:GTGG:G	donor_loss	1.0000
8:30156408:T:A	donor_loss	1.0000
8:30164109:A:AG	acceptor_gain	1.0000
8:30164110:G:GA	acceptor_gain	1.0000
8:30164110:GT:G	acceptor_gain	1.0000
8:30164172:ATCGG:A	donor_loss	1.0000
8:30164174:CGGT:C	donor_loss	1.0000

AlphaMissense

854 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:30101930:G:A	G17R	0.999
8:30101930:G:C	G17R	0.999
8:30101921:G:A	G14R	0.998
8:30101921:G:C	G14R	0.998
8:30101931:G:A	G17E	0.998
8:30105779:G:A	G105R	0.998
8:30105779:G:C	G105R	0.998
8:30105780:G:A	G105E	0.998
8:30105784:C:A	N106K	0.998
8:30105784:C:G	N106K	0.998
8:30101922:G:A	G14E	0.997
8:30101934:T:C	L18P	0.997
8:30101951:G:A	G24R	0.997
8:30101951:G:C	G24R	0.997
8:30104421:T:C	F72L	0.997
8:30104423:T:A	F72L	0.997
8:30104423:T:G	F72L	0.997
8:30104440:T:A	V78D	0.997
8:30104454:G:A	G83R	0.997
8:30104454:G:C	G83R	0.997
8:30104455:G:A	G83E	0.997
8:30104458:T:C	L84P	0.997
8:30104461:C:G	P85R	0.997
8:30101949:T:A	L23H	0.996
8:30104433:G:C	G76R	0.996
8:30105824:T:C	F120L	0.996
8:30105826:T:A	F120L	0.996
8:30105826:T:G	F120L	0.996
8:30101918:G:A	G13R	0.995
8:30101918:G:C	G13R	0.995

dbSNP variants (sampled 300 via entrez): RS1000003412 (8:30109580 C>A,T), RS1000101371 (8:30116125 C>T), RS1000124927 (8:30094660 A>G), RS1000161778 (8:30127613 G>A), RS1000219253 (8:30094900 G>C,T), RS1000236346 (8:30135319 T>C), RS1000285165 (8:30130572 A>C,G), RS1000289430 (8:30122640 A>C), RS1000455939 (8:30123899 G>A), RS1000533422 (8:30138158 C>T), RS1000556957 (8:30095757 G>A), RS1000579422 (8:30133400 A>G), RS1000671656 (8:30131472 A>G), RS1000702328 (8:30127902 A>G), RS1000826480 (8:30124248 A>G)

Disease associations

OMIM: gene MIM:607338 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): hereditary breast ovarian cancer syndrome (MONDO:0003582)

Orphanet (1): Hereditary breast and/or ovarian cancer syndrome (Orphanet:145)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression, increases expression	2
Benzene	increases expression	2
GSK-J4	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
beta-lapachone	decreases expression, increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sodium arsenite	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Air Pollutants	increases expression, affects cotreatment, increases abundance	1
Atrazine	decreases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Cadmium	decreases expression, increases abundance	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Ozone	increases abundance, affects cotreatment, increases expression	1
Rotenone	increases expression	1
Dronabinol	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1
Zinc	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

51 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02562170	PHASE4	COMPLETED	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
NCT00673335	PHASE3	COMPLETED	Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
NCT00685256	PHASE3	COMPLETED	Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
NCT03162276	PHASE3	UNKNOWN	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00253539	PHASE2	COMPLETED	Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
NCT00305695	PHASE2	COMPLETED	Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
NCT00321633	PHASE2	COMPLETED	Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
NCT01333748	PHASE2	COMPLETED	Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
NCT01367639	PHASE2	COMPLETED	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00535119	PHASE1	COMPLETED	Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
NCT00892736	PHASE1	COMPLETED	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
NCT03832985	EARLY_PHASE1	COMPLETED	Pediatric Reporting of Adult-Onset Genomic Results
NCT00005095	Not specified	RECRUITING	Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT00609505	Not specified	COMPLETED	Telemedicine vs. Face-to-Face Cancer Genetic Counseling
NCT01273909	Not specified	UNKNOWN	Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment
NCT01445275	Not specified	WITHDRAWN	Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
NCT01608074	Not specified	ACTIVE_NOT_RECRUITING	Radical Fimbriectomy for Young BRCA Mutation Carriers
NCT02087592	Not specified	COMPLETED	Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02302742	Not specified	RECRUITING	Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02324062	Not specified	COMPLETED	Cancer Genetics Hereditary Cancer Panel Testing
NCT02516540	Not specified	UNKNOWN	Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02653105	Not specified	ACTIVE_NOT_RECRUITING	Women at Risk of Breast Cancer and OLFM4
NCT02705924	Not specified	TERMINATED	Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
NCT02760849	Not specified	ACTIVE_NOT_RECRUITING	Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
NCT02786147	Not specified	COMPLETED	Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
NCT02956681	Not specified	COMPLETED	Statewide Communication to Reach Diverse Low Income Women
NCT03015376	Not specified	UNKNOWN	Inherited Susceptible Genes Among Epithelial Ovarian Cancer
NCT03050268	Not specified	RECRUITING	Familial Investigations of Childhood Cancer Predisposition
NCT03075540	Not specified	COMPLETED	Enhancing At-risk Latina Women’s Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer
NCT03124212	Not specified	RECRUITING	Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
NCT03246841	Not specified	ACTIVE_NOT_RECRUITING	Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
NCT03294343	Not specified	UNKNOWN	Risk-Reducing Surgeries for Hereditary Ovarian Cancer
NCT03421327	Not specified	COMPLETED	Genetic Risk: Whether, When, and How to Tell Adolescents
NCT03510689	Not specified	COMPLETED	Genetics and Heart Health After Cancer Therapy
NCT03511690	Not specified	COMPLETED	Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
NCT03784859	Not specified	COMPLETED	Tissue Expansion in Breast Reconstruction Without Drains
NCT03979612	Not specified	UNKNOWN	Evaluation of the Adhesion to the GENEPY Network
NCT04197856	Not specified	ACTIVE_NOT_RECRUITING	Direct Information to At-risk Relatives
NCT04407611	Not specified	COMPLETED	Scalable Communication Modalities for Returning Genetic Research Results
NCT04508764	Not specified	TERMINATED	Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome